FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer By Ogkologos - October 28, 2026 84 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research Bringing AI to the data: the future of privacy-compliant cancer research MOST POPULAR Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic... May 14, 2026 Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug... September 28, 2022 Twins Born 15 Minutes Apart Have Birthdays In Different Years January 9, 2022 Young Adult Cancer Awareness Week: Recognizing Adolescent and Young Adults Cancer... April 5, 2021 Load more HOT NEWS Experimental CAR T-Cell Therapy Shrinks Tumors in Children with Deadly Brain... Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical...
